RAFAEL
RUBIO GARCÍA
Profesor titular de universidad
![Foto de RAFAEL](/img/uploaded/6CA654DD031F6FEF08160B3A8AA5CC20.jpg)
![Foto de Hospital Universitario 12 de Octubre](/img/noimage_org.png)
Hospital Universitario 12 de Octubre
Madrid, EspañaPublicacions en col·laboració amb investigadors/es de Hospital Universitario 12 de Octubre (167)
2024
-
Acceptability of Long-Acting Injectable Antiretroviral Treatment for HIV Management: Perspectives of Patients and Physicians in Spain
AIDS Patient Care and STDs, Vol. 38, Núm. 7, pp. 305-314
2023
-
HIV medical care interruption among people living with HIV in Spain, 2004-2020
AIDS, Vol. 37, Núm. 8, pp. 1277-1284
-
Healthcare outcomes in patients with HIV infection at a tertiary hospital during the COVID-19 pandemic
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 41, Núm. 3, pp. 149-154
-
Post-mortem findings in Spanish patients with COVID-19; a special focus on superinfections
Frontiers in Medicine, Vol. 10
2022
-
Discovering HIV related information by means of association rules and machine learning
Scientific Reports, Vol. 12, Núm. 1
-
Epidemiological trends of HIV/HCV coinfection in Spain, 2015–2019
HIV Medicine, Vol. 23, Núm. 7, pp. 705-716
-
Long-term Evaluation of Residual Viremia in a Clinical Trial of Dolutegravir Plus Lamivudine as Maintenance Treatment for Participants With and Without Prior Lamivudine Resistance
Open Forum Infectious Diseases, Vol. 9, Núm. 11
-
Management of Comorbidities in Treated HIV Infection: A Long Way to Go: HIV, comorbidities and aging
International Journal of Antimicrobial Agents, Vol. 59, Núm. 1
2021
-
Cryptococcal infection in HIV-infected patients with CD4+ T-cell counts under 100/μL diagnosed in a high-income country: a multicentre cohort study
Clinical Microbiology and Infection, Vol. 27, Núm. 8, pp. 1171.e1-1171.e7
-
Detection of archived lamivudine-associated resistance mutations in virologically suppressed, lamivudine-experienced HIV-infected adults by different genotyping techniques (GEN-PRO study)
Journal of Antimicrobial Chemotherapy, Vol. 76, Núm. 12, pp. 3263-3271
-
Determinants of hiv-1 late presentation in patients followed in europe
Pathogens, Vol. 10, Núm. 7
-
Late presentation for HIV remains a major health issue in Spain: Results from a multicenter cohort study, 2004–2018
PLoS ONE, Vol. 16, Núm. 4 April
-
Redefining therapeutic success in HIV patients: An expert view
Journal of Antimicrobial Chemotherapy, Vol. 76, Núm. 10, pp. 2501-2518
2020
-
Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical Trials
Journal of acquired immune deficiency syndromes (1999), Vol. 85, Núm. 3, pp. 325-330
-
Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO)
EBioMedicine, Vol. 55
-
Efficacy and Freedom: Patient Experiences with the Transition from Daily Oral to Long-Acting Injectable Antiretroviral Therapy to Treat HIV in the Context of Phase 3 Trials
AIDS and Behavior, Vol. 24, Núm. 12, pp. 3473-3481
-
Prolonged administration of maraviroc reactivates latent HIV in vivo but it does not prevent antiretroviral-free viral rebound
Scientific Reports, Vol. 10, Núm. 1
-
Sustained virological response at week 12 after interferon-free therapy as criterion for HCV cure definition: Validation in a real-life cohort of HIV-coinfected patients
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 38, Núm. 6, pp. 275-278
-
Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997–2017)
Scientific Reports, Vol. 10, Núm. 1
2019
-
Analysis of the costs and cost-effectiveness of the guidelines recommended by the 2018 GESIDA/Spanish National AIDS Plan for initial antiretroviral therapy in HIV-infected adults
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 37, Núm. 3, pp. 151-159